



PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

ACCESSION NO: 0028WE000272

: RAJEM10058328A PATIENT ID

CLIENT PATIENT ID: ABHA NO

AGE/SEX :40 Years

RECEIVED : 13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status	Final	Results E	Biological Reference Interval	Units

ŀ	IAEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP B	ELOW 40 MALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	13.8	13.0 - 17.0	g/dL
METHOD : SPECTROPHOTOMETRY	4.05	45 55	
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.95	4.5 - 5.5	mil/μL
WHITE BLOOD CELL (WBC) COUNT	7.20	4.0 - 10.0	thou/µL
METHOD : ELECTRICAL IMPEDANCE			
PLATELET COUNT	120 Low	150 - 410	thou/µL
METHOD : ELECTRICAL IMPEDANCE			
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	42.6	40.0 - 50.0	%
METHOD : CALCULATED PARAMETER	06.3	02.0 101.0	EI.
MEAN CORPUSCULAR VOLUME (MCV) METHOD: DERIVED/COULTER PRINCIPLE	86.2	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	27.9	27.0 - 32.0	pg
METHOD: CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	32.4	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	16.7 High	11.6 - 14.0	%
MENTZER INDEX	17.4		
METHOD : CALCULATED PARAMETER	2711		
MEAN PLATELET VOLUME (MPV) METHOD: DERIVED/COULTER PRINCIPLE	12.6 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	59	40 - 80	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY			
LYMPHOCYTES	29	20 - 40	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY			

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist





Page 1 Of 23







PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:

CIN - U74899PB1995PLC045956 Email: customer care.no ida@srl.in







PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID: ABHA NO

AGE/SEX :40 Years

DRAWN

RECEIVED : 13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
MONOCYTES	9	2.0 - 10.0	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY			
EOSINOPHILS	3	1.0 - 6.0	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY			
BASOPHILS	0	0 - 1	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY			
ABSOLUTE NEUTROPHIL COUNT	4.20	2.0 - 7.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	2.00	1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.70	0.2 - 1.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.22	0.02 - 0.50	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE BASOPHIL COUNT	0.00 Low	0.02 - 0.10	thou/µL
METHOD: CALCULATED PARAMETER			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	2.1		
METHOD: CALCULATED PARAMETER			

MORPHOLOGY

REMARKS

THE PLATELET COUNT HAS BEEN PERFORMED BY VISUAL ASSESSMENT OF THE PERIPHERAL BLOOD SMEAR DUE TO THE PRESENCE OF GIANT PLATELETS EACH PLATELET /FIELD UNDER OIL IMMERSION (100X) WAS TAKEN TO REPRESENT 10,000 PLATELETS /MICROLITRE OF BLOOD. REFERENCE: WINTROBE'S CLINICAL HEMATOLOGY, 11TH EDITION (2004).

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.


(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 2 Of 23





Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138361

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID:

ABHA NO

:40 Years AGE/SEX

RECEIVED : 13/05/2023 08:47:25

REPORTED :17/05/2023 12:26:03

Biological Reference Interval **Test Report Status** Results Units <u>Final</u>

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

< 15 mm at 1 hr E.S.R

METHOD: MODIFIED WESTERGREN METHOD BY AUTOMATED ANALYSER

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis)

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. **Decreased** in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist





Page 3 Of 23





Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138361

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID: ABHA NO

AGE/SEX

:40 Years

RECEIVED : 13/05/2023 08:47:25

REPORTED :17/05/2023 12:26:03

Test Report Status Results Biological Reference Interval Units <u>Final</u>

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

TYPE B **ABO GROUP**

METHOD: COLUMN AGGLUTINATION TECHOLOGY

RH TYPE POSITIVE

METHOD: COLUMN AGGLUTINATION TECHOLOGY

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for

The test is performed by both forward as well as reverse grouping methods.

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist





Page 4 Of 23





Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

METHOD: HEXOKINASE

ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID: ABHA NO

AGE/SEX

:40 Years DRAWN

RECEIVED : 13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status Results **Biological Reference Interval Units** <u>Final</u>

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)

90

74 - 106

mg/dL

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

BLOOD

HBA1C 5.0 Non-diabetic Adult < 5.7

Pre-diabetes 5.7 - 6.4

Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0

(ADA Guideline 2021)

METHOD: HPLC

ESTIMATED AVERAGE GLUCOSE(EAG)

96.8

< 116.0

mg/dL

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

80

Non-Diabetes 70 - 140


mg/dL

METHOD : HEXOKINASE

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 5 Of 23



Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138361

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID: ABHA NO : AGE/SEX :40 Years
DRAWN :

RECEIVED :13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Comments

Causes of Low Post Prandial Blood Sugar

The causes of low blood sugar that occurs following a meal have been divided traditionally into

- (1)Alimentary
- (2)Functional and
- (3) That in diabetics and those with impaired glucose tolerance

Alimentary Hypoglycemia usually, but not necessarily, occurs in those patients who have had gastrointestinal surgery. Accelerated absorption of a glucose load leads to marked post - prandial hyperglycemia with a corresponding exaggerated insulin release thus resulting in hypoglycemia the ensuing hypoglycemia typically occurs from one and one half to three hours after eating. This pattern of glucose intolerance and a history of gastrointestinal surgery are suggestive of the diagnosis.

Functional Hypoglycemia is quite common in adults; it may be characterized by abnormally low plasma glucose and symptoms of light headedness, shakiness, diaphoresis, weakness, fatigue occurring with the modest withholding of food. Complaints suggestive of this syndrome commonly are seen in those who have emotional problems.

Post Prandial Hypoglycemia in diabetics: Patients who are diabetics or who have impaired glucose tolerance also may experience reactive hypoglycemia. In these patients, hypoglycemia occurs later than in the group with the alimentary disorder, and insulin response is delayed and exaggerated.

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL	181	< 200 Desirable	mg/dL
		200 - 239 Borderline High	
		>/= 240 High	
METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE	:	· ·	

TRIGLYCERIDES	179 High	< 150 Normal	mg/dL
---------------	----------	--------------	-------

150 - 199 Borderline High 200 - 499 High

>/= 500 Very High

HDL CHOLESTEROL 51 < 40 Low >/=60 High

METHOD : DIRECT MEASURE POLYMER-POLYANION

CHOLESTEROL LDL 94 < 100 Optimal mg/dL

100 - 129 Near or above optimal

130 - 159
Borderline High
160 - 189
High
>/= 190
Very High

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 6 Of 23







Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:

Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email: customercare.noida@srl.in



mg/dL





CODE/NAME & ADDRESS: C000138361 ACCESSION NO: 0028WE000272 AGE/SEX :40 Years Male

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED : 13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

	<u> </u>	
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
NON HDL CHOLESTEROL	130	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220
METHOD: CALCULATED PARAMETER		
VERY LOW DENSITY LIPOPROTEIN	35.8 High	Desirable value : mg/dL 10 - 35
CHOL/HDL RATIO	3.6	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk
LDL/HDL RATIO	1.8	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category				
Extreme risk group	A.CAD with > 1 feature of high risk group			
	B. CAD with > 1 feature of Very high risk g	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or =		
	50 mg/dl or polyvascular disease			
Very High Risk	1. Established ASCVD 2. Diabetes with 2 i	najor risk factors or evidence of end organ damage 3.		
	Familial Homozygous Hypercholesterolemi	a		
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ			
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary			
	Artery Calcium - CAC > 300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque			
Moderate Risk	2 major ASCVD risk factors			
Low Risk	0-1 major ASCVD risk factors	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	ictors		
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use				
2. Family history of premature ASCVD 4. High blood pressure				
5. Low HDL				
T	1	11 7 47 4000		

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group **Treatment Goals Consider Drug Therapy**

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 7 Of 23







PERFORMED AT :
Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







CODE/NAME & ADDRESS: C000138361 ACCESSION NO: 0028WE000272 AGE/SEX :40 Years Male

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID:

ABHA NO

DRAWN

RECEIVED : 13/05/2023 08:47:25

REPORTED :17/05/2023 12:26:03

Test Report Status Results Biological Reference Interval Units <u>Final</u>

	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	<OR = 60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL 0.82 UPTO 1.2	mg/dL
METHOD: DIAZONIUM ION, BLANKED (ROCHE)	
BILIRUBIN, DIRECT 0.28 0.00 - 0.30	mg/dL
METHOD: DIAZOTIZATION	
BILIRUBIN, INDIRECT 0.54 0.00 - 0.60	mg/dL
METHOD : CALCULATED PARAMETER	
TOTAL PROTEIN 7.4 6.6 - 8.7	g/dL
METHOD: BIURET, SERUM BLANK, ENDPOINT	
ALBUMIN 4.8 3.97 - 4.94	g/dL
METHOD: BROMOCRESOL GREEN	
GLOBULIN 2.6 2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD : CALCULATED PARAMETER	
ALBUMIN/GLOBULIN RATIO 1.9 1.0 - 2.0	RATIO
METHOD: CALCULATED PARAMETER	
ASPARTATE AMINOTRANSFERASE(AST/SGOT) 24 0 - 40	U/L
METHOD: UV WITHOUT P5P	117
ALANINE AMINOTRANSFERASE (ALT/SGPT) 29 0 - 41 METHOD: UV WITHOUT P5P	U/L
ALKALINE PHOSPHATASE 136 High 40 - 129	U/L
METHOD: PNPP, AMP BUFFER-IFCC	
GAMMA GLUTAMYL TRANSFERASE (GGT) 12 8 - 61	U/L
METHOD : G-GLUTAMYL-CARBOXY-NITROANILIDE-IFCC	
LACTATE DEHYDROGENASE 200 135 - 225	U/L
METHOD: L TO P, IFCC	

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist





Page 8 Of 23







PERFORMED AT :
Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







mg/dL

g/dL

PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138361

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID: ABHA NO : AGE/SEX :40 Years

A\A/NI .

RECEIVED :13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status <u>Final</u> Results Biological Reference Interval Units

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN 11 6 - 20 mg/dL

METHOD: UREASE - UV

CREATININE, SERUM

CREATININE

0.97

0.70 - 1.20

METHOD: ALKALINE PICRATE-KINETIC

BUN/CREAT RATIOBUN/CREAT RATIO

11.34

5.00 - 15.00

METHOD: CALCULATED PARAMETER

 URIC ACID, SERUM

 URIC ACID
 6.7
 3.4 - 7.0
 mg/dL

METHOD : URICASE, COLORIMETRIC

TOTAL PROTEIN, SERUM

6.6 - 8.7

7.4

METHOD: BIURET, SERUM BLANK, ENDPOINT

ALBUMIN, SERUM

ALBUMIN 4.8 3.97 - 4.94 g/dL

METHOD: BROMOCRESOL GREEN

TOTAL PROTEIN

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 9 Of 23







Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID: ABHA NO

AGE/SEX :40 Years

DRAWN

RECEIVED : 13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
GLOBULIN			
GLOBULIN			
GLOBULIN	2.6	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD : CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM METHOD: ISE INDIRECT	141	136 - 145	mmol/L
POTASSIUM, SERUM METHOD: ISE INDIRECT	4.22	3.5 - 5.1	mmol/L
CHLORIDE, SERUM METHOD: ISE INDIRECT	102	98 - 107	mmol/L

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist





Page 10 Of 23







PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:

CIN - U74899PB1995PLC045956 Email: customer care.no ida@srl.in









CODE/NAME & ADDRESS : C000138361

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID:

AGE/SEX DRAWN

Male

:40 Years

RECEIVED: 13/05/2023 08:47:25

REPORTED :17/05/2023 12:26:03

Test Report Status <u>Final</u> Results

ABHA NO

Biological Reference Interval Units

Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.

Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.

Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in : Diabetes mellitus, Cushing's syndrome (10-15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed,Alimentary Hypoglycemia,Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels
 eAG gives an evaluation of blood glucose levels for the last couple of months.
- 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results (possibly by inhibiting glycation of hemoglobin 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is

recommended for detecting a hemoglobinopathy
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin wher there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction,

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 11 Of 23

View Report



Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







CODE/NAME & ADDRESS : C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID:

AGE/SEX

:40 Years Male

DRAWN

RECEIVED : 13/05/2023 08:47:25

REPORTED :17/05/2023 12:26:03

Results **Biological Reference Interval Test Report Status** Units <u>Final</u>

ABHA NO

Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic

syndrome, Protein-losing enteropathy etc. **Albumin** is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy
URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome **Causes of decreased levels**-Low Zinc intake,OCP,Multiple Sclerosis
TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist





Page 12 Of 23







Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email: customercare.noida@srl.in



PERFORMED AT:





PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138361
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID:

AGE/SEX :40 Years

DRAWN :

RECEIVED :13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD : VISUAL

APPEARANCE CLEAR

METHOD: VISUAL

CHEMICAL EXAMINATION, URINE

PH	6.0	4.7 - 7.5
METHOD: DOUBLE INDICATOR PRINCIPLE		

SPECIFIC GRAVITY 1.020 1.003 - 1.035

METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES

PROTEIN NOT DETECTED NOT DETECTED

METHOD: PROTEIN- ERROR INDICATOR

GLUCOSE

NOT DETECTED

NOT DETECTED

METHOD : OXIDASE-PEROXIDASE REACTION

KETONES

NOT DETECTED

NOT DETECTED

METHOD : ACETOACETIC REACTION WITH NITROPRUSSIDE

BLOOD NOT DETECTED NOT DETECTED

METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN

BILIRUBIN

NOT DETECTED

NOT DETECTED

METHOD: DIAZOTIZATION
UROBILINOGEN NORMAL NORMAL

METHOD : MODIFIED EHRLICH REACTION

NITRITE NOT DETECTED NOT DETECTED

METHOD: CONVERTION OF NITRATE TO NITRITE

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

METHOD: ESTERASE HYDROLYSIS ACTIVITY

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) 1-2 0-5 /HPF

Verna

Page 13 Of 23

Dr. Neena Verma Senior Pathologist





View Details

View Report



Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138361
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : **0028WE000272**

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID: ABHA NO : AGE/SEX :40 Years

DRAWN :

RECEIVED :13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status	Final	Results	Biological Reference Interval	Units
i cot itcpoi t otatas	I IIIai	icouito	Diviogical Reference Interval	011163

METHOD: MICROSCOPIC EXAMINATION

EPITHELIAL CELLS 1-2 0-5 /HPF

METHOD: MICROSCOPIC EXAMINATION

CASTS NOT DETECTED METHOD: MICROSCOPIC EXAMINATION

CRYSTALS NOT DETECTED

METHOD : MICROSCOPIC EXAMINATION

BACTERIA NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

YEAST

NOT DETECTED

NOT DETECTED

REMARKS

MICROSCOPIC EXAMINATION DONE ON CENTRIFUGED URINEPLEASE NOTE THAT GRADING OF BACTERIA NEEDS TO BE CORELATED WITH THE CULTURE IN CASE FOUND SIGNIFICANT CLINICALLY. OCCASIONAL BACTERIA/YEAST CELLS SEEN IN MICROSCOPY CAN BE A PART OF

SURROUNDING SKIN FLORA ALSO.

METHOD: MANUAL

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions			
Proteins	Inflammation or immune illnesses			
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind			
	of kidney impairment			
Glucose	Diabetes or kidney disease			
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst			
Urobilinogen	Liver disease such as hepatitis or cirrhosis			
Blood	Renal or genital disorders/trauma			
Bilirubin	Liver disease			
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary			
	tract infection and glomerular diseases			
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either			
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by			
	genital secretions			
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or			
	bladder catheters for prolonged periods of time			

Dr. Neena Verma

Senior Pathologist

Page 14 Of 23





View Details

View Report



Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138361

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID: ABHA NO

AGE/SEX :40 Years

RECEIVED : 13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status Results Biological Reference Interval Units <u>Final</u>

Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,
	interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal
-	diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous
	infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl
	oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of
	ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Neena Verma **Senior Pathologist**



Page 15 Of 23





PERFORMED AT :
Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138361 ACCESSION NO : **0028WE000272** AGE/SEX : 40 Years

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID:

ABHA NO :

MOL/OLX 110 1

DRAWN :
RECEIVED :13/05/2023 08:47:25

REPORTED :17/05/2023 12:26:03

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

THYROID PANEL, SERUM

T3 133.0 80.00 - 200.00 ng/dL

METHOD : ECLIA

T4 7.37 5.10 - 14.10 $\mu g/dL$

METHOD : ECLIA

TSH (ULTRASENSITIVE) **4.590 High** 0.270 - 4.200 µIU/mL

METHOD : ECLIA

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 16 Of 23

View Details





Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:









CODE/NAME & ADDRESS: C000138361 ACCESSION NO: 0028WE000272 AGE/SEX :40 Years Male

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

: RAJEM10058328A PATIENT ID

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED : 13/05/2023 08:47:25

REPORTED :17/05/2023 12:26:03

Test Report Status Results Biological Reference Interval Units <u>Final</u>

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist





Page 17 Of 23

View Report



Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:

CIN - U74899PB1995PLC045956 Email: customercare.noida@srl.in





ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID:

ABHA NO :

, ,

DRAWN :
RECEIVED :13/05/2023 08:47:25

REPORTED :17/05/2023 12:26:03

Test Report Status <u>Final</u> Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

XRAY-CHEST

»» BOTH THE LUNG FIELDS ARE CLEAR

»»
BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR

»» BOTH THE HILA ARE NORMAL

CARDIAC AND AORTIC SHADOWS APPEAR NORMALBOTH THE DOMES OF THE DIAPHRAM ARE NORMAL

»»
VISUALIZED BONY THORAX IS NORMAL

IMPRESSION NORMAL

TMT OR ECHO

TMT OR ECHO TMT DONE - NORMAL

ECG

ECG WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY CHRONIC COUGH.

RELEVANT PAST HISTORY COVID POSITOVE APRIL 2021.
RELEVANT PERSONAL HISTORY MARRIED,NON,VEGETARIAN.

RELEVANT FAMILY HISTORY MOTHER-HTN.
FATHER-DIABETIC.

OCCUPATIONAL HISTORY
HISTORY OF MEDICATIONS
NOT SIGNIFICANT
NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.70 mts

Page 18 Of 23





View Details

View Report





CODE/NAME & ADDRESS : C000138361 ACCESSION NO: 0028WE000272 AGE/SEX :40 Years Male

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : RAJEM10058328A F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

CLIENT PATIENT ID:

DRAWN

RECEIVED : 13/05/2023 08:47:25

REPORTED :17/05/2023 12:26:03

Test Report Status	Final	Results	Biological Reference Interval	Units

ABHA NO

WEIGHT IN KGS. 72.8 Kgs

BMI 25 BMI & Weight Status as follows/sqmts

> Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE **NORMAL NORMAL** PHYSICAL ATTITUDE GENERAL APPEARANCE / NUTRITIONAL **HEALTHY**

STATUS

AVERAGE BUILT / SKELETAL FRAMEWORK FACIAL APPEARANCE **NORMAL NORMAL** SKIN UPPER LIMB **NORMAL** NORMAL LOWER LIMB NORMAL **NECK**

NOT ENLARGED OR TENDER NECK LYMPHATICS / SALIVARY GLANDS

NOT ENLARGED THYROID GLAND NORMAL

CAROTID PULSATION **TEMPERATURE NORMAL**

PULSE 83 / MIN REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

BRUIT

NORMAL RESPIRATORY RATE

CARDIOVASCULAR SYSTEM

BP 136/79 mm/Hg

NORMAL PERICARDIUM NORMAL APEX BEAT **HEART SOUNDS NORMAL MURMURS ABSENT**

Page 19 Of 23



View Report





PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138361
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID:

AGE/SEX :40 Years

DRAWN :

RECEIVED :13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status <u>Final</u> Results Biological Reference Interval Units

ABHA NO

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST

MOVEMENTS OF CHEST

BREATH SOUNDS INTENSITY

NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

PER ABDOMEN

APPEARANCE NORMAL
VENOUS PROMINENCE ABSENT
LIVER NOT PALPABLE
SPLEEN NOT PALPABLE

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS NORMAL
CRANIAL NERVES NORMAL
CEREBELLAR FUNCTIONS NORMAL
SENSORY SYSTEM NORMAL
MOTOR SYSTEM NORMAL
REFLEXES NORMAL

MUSCULOSKELETAL SYSTEM

SPINE NORMAL JOINTS NORMAL

Page 20 Of 23







View Report





PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138361 ACCESSION NO: 0028WE000272 AGE/SEX

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID: ABHA NO

:40 Years

DRAWN

RECEIVED : 13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status Results Biological Reference Interval Units <u>Final</u>

BASIC EYE EXAMINATION

NORMAL CONJUNCTIVA EYELIDS NORMAL EYE MOVEMENTS NORMAL **CORNEA NORMAL** DISTANT VISION RIGHT EYE WITHOUT 6/12 **GLASSES** DISTANT VISION LEFT EYE WITHOUT 6/12 **GLASSES** NEAR VISION RIGHT EYE WITHOUT GLASSES NORMAL NEAR VISION LEFT EYE WITHOUT GLASSES NORMAL NORMAL **COLOUR VISION**

BASIC ENT EXAMINATION

EXTERNAL EAR CANAL **NORMAL** NORMAL TYMPANIC MEMBRANE

NOSE NO ABNORMALITY DETECTED

NORMAL **SINUSES**

NO ABNORMALITY DETECTED **THROAT**

TONSILS NOT ENLARGED

BASIC DENTAL EXAMINATION

TEETH **NORMAL**

GUMS CALCULUS PRESENT.

SUMMARY

NOT SIGNIFICANT RELEVANT HISTORY

Page 21 Of 23





View Report





PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID: ABHA NO

AGE/SEX: 40 Years

DRAWN

RECEIVED : 13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status Results Biological Reference Interval Units <u>Final</u>

RELEVANT GP EXAMINATION FINDINGS RELEVANT LAB INVESTIGATIONS RELEVANT NON PATHOLOGY DIAGNOSTICS REMARKS / RECOMMENDATIONS

NOT SIGNIFICANT WITHIN NORMAL LIMITS NO ABNORMALITIES DETECTED

"NO ABNORMALITY FOUND OUT OF THE DIAGNOSTIC PACKAGE REQUESTED. GENERAL PHYSICAL EXAMINATION IS NORMAL."

Page 22 Of 23









PERFORMED AT :
Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar, Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India





PATIENT NAME: RAJESH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138361

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0028WE000272

PATIENT ID : RAJEM10058328A

CLIENT PATIENT ID: ABHA NO : AGE/SEX :40 Years

DRAWN :

RECEIVED :13/05/2023 08:47:25 REPORTED :17/05/2023 12:26:03

Test Report Status <u>Final</u> Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

BORDERLINE PROSTATOMEGALY

Interpretation(s)

MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062


Page 23 Of 23





View Details

View Report



Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar,Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India

